·
A board-certified neurologist with more than 25 years of clinical
experience, Dr. James C. Johnston maintains a private practice and
serves as a partner with Global Neurology Consultants. Dr. James C.
Johnston obtained his medical degree from the University of Texas Health
Science Center in San Antonio. He performed a general surgery
internship at the University of Texas Health Science Center, and
completed neurology residency at the Texas Medical Center in Houston.
As a leading health care provider in the University of Texas network, the
Cancer Therapy & Research Center (CTRC) at the UT Health Science
Center has continuously worked to provide residents of the South Texas
region with access to advanced cancer care since opening its doors in
1974. Maintaining its role as a leader in cancer research and
prevention, the CTRC recently launched a new clinical trial targeted at
brain cancer. Headed by Andrew Brenner, MD, PhD, a neuro-oncologist at
the CTRC, the trial involves loading fat particles with “very high
radioactivity levels” and implanting miniscule quantities of the
particles directly into the tumor with high-precision instruments.
Because the new procedure involves irradiating the tumor from within,
healthy tissues and organs such as the kidney, liver, or bone marrow are
not exposed to high levels of radiation. Preclinical animal trials
showed that tumors disappeared in an average of 70 days after treatment.
experience, Dr. James C. Johnston maintains a private practice and
serves as a partner with Global Neurology Consultants. Dr. James C.
Johnston obtained his medical degree from the University of Texas Health
Science Center in San Antonio. He performed a general surgery
internship at the University of Texas Health Science Center, and
completed neurology residency at the Texas Medical Center in Houston.
As a leading health care provider in the University of Texas network, the
Cancer Therapy & Research Center (CTRC) at the UT Health Science
Center has continuously worked to provide residents of the South Texas
region with access to advanced cancer care since opening its doors in
1974. Maintaining its role as a leader in cancer research and
prevention, the CTRC recently launched a new clinical trial targeted at
brain cancer. Headed by Andrew Brenner, MD, PhD, a neuro-oncologist at
the CTRC, the trial involves loading fat particles with “very high
radioactivity levels” and implanting miniscule quantities of the
particles directly into the tumor with high-precision instruments.
Because the new procedure involves irradiating the tumor from within,
healthy tissues and organs such as the kidney, liver, or bone marrow are
not exposed to high levels of radiation. Preclinical animal trials
showed that tumors disappeared in an average of 70 days after treatment.
